Volume 4, Issue 3 ( Journal of Clinical and Basic Research (JCBR) 2020)
jcbr 2020, 4(3): 34-39 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kamkar M Z, Siamaki Khaboshan F, Marjani A. Comparison of Serum Zinc Levels between Patients with Schizophrenia and Healthy Individuals. jcbr 2020; 4 (3) :34-39
URL: http://jcbr.goums.ac.ir/article-1-273-en.html
URL: http://jcbr.goums.ac.ir/article-1-273-en.html
1- Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (2974 Views)
Background and objectives: Schizophrenia is a debilitating mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Zinc is a neuroactive element released in synapses during neuronal activity and is required for proper functioning of the nervous system, particularly the brain. Serum and tissue concentrations of zinc may reflect various physiological and pathophysiological conditions. Evidence suggests a link between zinc level and development of schizophrenia. The aim of this study was to compare serum zinc levels between patients with schizophrenia and healthy individuals.
Methods: This case-control study was performed on 55 patients (37 men and 18 women) with schizophrenia who were hospitalized in 5 Azar Hospital in Gorgan (Iran) and 55 healthy individuals. The case subjects were selected based on convenience sampling method using the Positive and Negative Syndrome Scale (PANSS), while the control subjects were enrolled based on the General Health Questionnaire-28 (GHQ-28). The groups were matched in terms of age and gender. Serum concentration of zinc was measured using a commercial colorimetric assay kit (5-Br-PAPS method).
Results: Serum zinc concentration did not differ significantly between the patients and the controls (P=0.93). In schizophrenic patients, there was a significant, negative correlation between age and serum zinc concentration (r=-0.298, P=0.027). In both patients and controls, serum zinc level was significantly higher in men than in women (P<0.05).
Conclusion: Based on the results, it is recommended to pay more attention to the diet of patients with schizophrenia.
Methods: This case-control study was performed on 55 patients (37 men and 18 women) with schizophrenia who were hospitalized in 5 Azar Hospital in Gorgan (Iran) and 55 healthy individuals. The case subjects were selected based on convenience sampling method using the Positive and Negative Syndrome Scale (PANSS), while the control subjects were enrolled based on the General Health Questionnaire-28 (GHQ-28). The groups were matched in terms of age and gender. Serum concentration of zinc was measured using a commercial colorimetric assay kit (5-Br-PAPS method).
Results: Serum zinc concentration did not differ significantly between the patients and the controls (P=0.93). In schizophrenic patients, there was a significant, negative correlation between age and serum zinc concentration (r=-0.298, P=0.027). In both patients and controls, serum zinc level was significantly higher in men than in women (P<0.05).
Conclusion: Based on the results, it is recommended to pay more attention to the diet of patients with schizophrenia.
Article Type: Research |
Subject:
Basic medical sciences
References
1. Takeda A, Tamano H. Insight into zinc signaling from dietary zinc deficiency. Brain research reviews. 2009; 62(1):33-44. DOI:
10.1016/j.brainresrev.2009.09.003. Source. PubMed. [View at Publisher] [PubMed] [Google Scholar]
2. Hanafi I, Arafat S, Al Zayed L, Sukkar M, Albeirakdar A, Krayem D, Essali A. Haloperidol (route of administration) for people with schizophrenia. Cochrane Systematic Review - Intervention - Protocol Version published: 19 October 017. [View at Publisher] [DOI] [Google Scholar]
3. Mössner R, Schuhmacher A, Wagner M, Lennertz L. Steinbrecher A, Quednow BB, Rujescu D, Rietschel M, Maier W. The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. European archives of psychiatry and clinical neuroscience. 2011; 262(3):193-7. [View at Publisher] [DOI] [PubMed] [Google Scholar]
4. 40 David CN, Greenstein D, Clasen L, Gochman P, Miller R, Tossell JW,et al. Childhood onset schizophrenia: High rate of visual hallucinations. J Am Acad Child Adolesc Psychiatry.2011;50(7):681-6. [View at Publisher] [DOI] [PubMed] [Google Scholar]
5. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. Schizophr Res Treatment. 2012;2012: 916198 doi: 10.1155/2012/916198 [PubMed] [Google Scholar]
6. Meaney AM, O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J Psychopharmacol. 2003;17(4):455-8. [View at Publisher] [DOI] [PubMed] [Google Scholar]
7. Crespo-Facorro B, Barbadillo L, Pelayo-Terán JM, Rodríguez-Sánchez JM. Neuropsychological functioning and brain structure in schizophrenia. International Review of Psychiatry. 2007; 19(4):325-36. [View at Publisher] [DOI] [PubMed] [Google Scholar]
8. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. The British Journal of Psychiatry. 2007;190(2):129-134. [View at Publisher] [DOI] [PubMed] [Google Scholar]
9. Szczotka J, Majchrowicz B. Schizophrenia as a disorder of embodied self. Psychiatr Pol. 2018;52(2):199-215. [DOI] [PubMed] [Google Scholar]
10. Farzin D, Mansouri NA, Yazdani T, EBRAHIMI P, ZARGHAMI M, AZARI P, et al. Elevated plasma copper/zinc ratios in patients with schizophrenia. 2007;9(1):14-9. [View at Publisher] [Google Scholar]
11. Grønli O, Kvamme JM, Friborg O, Wynn R. Zinc deficiency is common in several psychiatric disorders. PLoS One. 2013;8(12). [View at Publisher] [DOI] [PubMed] [Google Scholar]
12. Ghanem AA, Ali EM, El-Bakary A, El-Morsy D, Elkanishi S, Saleh E-S, et al. Copper and Zinc Levels in Hair of Both Schizophrenic and Depressed Patients. Mansoura J Forensic Med Clin Toxicol. 2009;17(1):89-102. [DOI] [Google Scholar]
13. King JC. Zinc: an essential but elusive nutrient. Am J Clin Nutr. 2011 Aug
94(2): 679S-684S. Published online 2011 Jun 29. doi: 10.3945/ajcn.110.005744. [View at Publisher] [DOI] [PubMed] [Google Scholar]
14. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. November 2011Archives of Toxicology 86(4):521-34. Follow journal.DOI: 10.1007/s00204-011-0775-1. Source. PubMed. [View at Publisher] [DOI] [PubMed] [Google Scholar]
15. Lichten LA, Ryu MS, Guo L, Embury J, Cousins RJ. MTF-1-mediated repression of the Zinc transporter Zip10 is alleviated by Zinc restriction. [View at Publisher] [DOI] [PubMed] [Google Scholar]
16. Joe P, Petrilli M, Malaspina D, Weissman J. Zinc in schizophrenia: a meta-analysis. Gen Hosp Psychiatry. 2018;53:19-24. [View at Publisher] [DOI] [PubMed] [Google Scholar]
17. Petrilli MA, Kranz TM, Kleinhaus K, Joe P, Getz M, Johnson P, Chao MV, Malaspina D. The emerging role for zinc in depression and psychosis. Front. Pharmacol. 30 June 2017 | [View at Publisher] [DOI] [PubMed] [Google Scholar]
18. Craven C, Duggan PF, Buckley N, Gaughran F. Serum zinc levels in patients with schizophrenia and their mothers. Schizophrenia research. 1997; 26(1):83-4. [View at Publisher] [DOI] [PubMed] [Google Scholar]
19. Yanik M, Kocyigit A, Tutkun H, Vural H, Herken H. Plasma manganese, selenium, zinc,
copper, and iron concentrations in patients with schizophrenia. Biol Trace Elem Res. 2004;98(2):109-17. [View at Publisher] [DOI] [PubMed] [Google Scholar]
20. Vidović B, Crossed D Signorcrossed D Signević B, Milovanović SDS, Škrivanj S, Pavlović Z, Stefanović A, et al. Selenium, zinc, and copper plasma levels in patients with schizophrenia: relationship with metabolic risk factors. Biol Trace Elem Res. 2013;156(1-3):22-8. [View at Publisher] [DOI] [PubMed] [Google Scholar]
21. Cai L, Chen T, Yang J, Zhou K, Yan X, Chen W, et al. Serum trace element differences between Schizophrenia patients and controls in the Han Chinese population. Sci Rep. 2015;5:15013. [View at Publisher] [DOI] [PubMed] [Google Scholar]
22. Chen X, Li Y, Zhang T, Yao Y, Shen C, Xue Y. Association of Serum Trace Elements with Schizophrenia and Effects of Antipsychotic Treatment. Biol Trace Elem Res. 2018;181(1):22-30. [View at Publisher] [DOI] [PubMed] [Google Scholar]
23. 23 Hjelle EG, Bragstad LK, Zucknick M, Kirkevold M, Thommessen B, Sveen U. The General Health Questionnaire-28 (GHQ-28) as an outcome measurement in a randomized controlled trial in a Norwegian stroke population. BMC Psychol 7, 18 (2019). [View at Publisher] [DOI] [PubMed] [Google Scholar]
24. Olesen RH, Hyde TM, Kleinman JE, Smidt K, Rungby J, Larsen A. Obesity and age-related alterations in the gene expression of zinc-transporter proteins in the human brain. Transl Psychiatry.2016;6(6):e838. doi:10.1038/tp.2016.83. [View at Publisher] [PubMed] [Google Scholar]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).